Artis BioSolutions opens manufacturing center in Bilbao for genetic medicines
These therapies can require multiple stages, including DNA starting materials, RNA production, targeted delivery technologies, formulation, analytical testing and scalable drug product manufacturing.
SPAIN—Artis BioSolutions has opened a new manufacturing center in Bilbao, Spain, expanding the contract development and manufacturing organization’s (CDMO) capabilities for next-generation genetic medicines.
The company’s new Genetic Medicines Center of Excellence provides integrated development and manufacturing services spanning synthetic DNA, messenger RNA (mRNA) drug substance, lipid nanoparticle (LNP) formulation, and production, according to an Aug. 26 company release.
Artis said the center brings several technologies and manufacturing capabilities under one organization, allowing customers to advance genetic medicine programs from early development through commercial production.
The company did not disclose the financial investment in the facility.
“The future of genetic medicines demands new innovations and integrated partners that can seamlessly support the advancement of new therapeutic targets from development through commercialization,” said Brian Neel, chief executive officer of Artis BioSolutions.
He added that combining synthetic DNA, mRNA and LNP technologies with good manufacturing practice (GMP) production creates a continuous platform that can help customers shorten development timelines, reduce complexity and costs, and accelerate the delivery of new therapies to patients.
Addressing manufacturing complexity
Artis designed the Bilbao facility to address the growing complexity of genetic medicine manufacturing.
These therapies can require multiple stages, including DNA starting materials, RNA production, targeted delivery technologies, formulation, analytical testing and scalable drug product manufacturing.
The company said developers often rely on several specialized suppliers to complete these activities.
As a result, programs can face complicated technology transfers, longer timelines and additional operational costs as materials and processes move between vendors.
“The genetic medicines landscape has evolved rapidly, but development remains significantly fragmented,” said Peter Stolba, chief business officer at Artis BioSolutions.
The new center aims to reduce that fragmentation by offering customers a single partner for activities ranging from starting-material production to commercialization, Stolba said.
Expansion of Artis’ manufacturing network
Artis BioSolutions, headquartered in San Diego, California, began operating as a CDMO in April 2025 after acquiring Landmark Bio for an undisclosed amount.
The acquisition also expanded Artis’ manufacturing footprint in the United States.
As part of the transaction, the company acquired a 44,000-square-foot production facility in Watertown, Massachusetts.
The Massachusetts site supports the development and manufacturing of cell and gene therapies and genome-editing products.
It also provides fill-finish services and manufactures viral vectors, mRNA and lipid nanoparticles.
The Bilbao center adds capabilities focused specifically on genetic medicines to Artis’ broader manufacturing network.
Through the new facility, the company will provide development and production services covering multiple stages of the genetic medicine manufacturing process within its organization.
.
Be the first to leave a comment